Project Grant R01AI179950

Award Date 6/6/24
Completion Date 4/30/29
Dollars Obligated $2.7M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
The University of Georgia Research Foundation was awarded a $540,193 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 12-month award, effective August 22, 2023, supports research to investigate the role of calcium-binding proteins and other secretory pathway components in the exocytosis of organelles critical for the invasion and egress of the malaria parasite Plasmodium falciparum...
This $215,751 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to identify and characterize RNA-binding proteins (RBPs) and RNA-dependent proteins (RDPs) in the malaria parasite Plasmodium falciparum. The research team at the University of California, Riverside will use an unbiased proteome-wide approach, called R-DEEP, to detect RBPs and RDPs during the parasite's sexual...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This $924,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the mechanism of knob formation in Plasmodium falciparum-infected red blood cells and develop new therapeutic approaches to disrupt cytoadhesion in human malaria. The primary awardee, Trustees of Tufts College (Tufts University School of Medicine), will use advanced biochemical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $375,000.00 in funding to the University of South Florida to conduct research on the functions of messenger ribonucleoproteins (mRNPs) in regulating RNA metabolism in the malaria parasite Plasmodium falciparum. The key objectives of this 5-year research project are to: 1) identify molecular markers for distinct mRNP...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $800,972 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) to conduct research on profiling malarial lipid biosynthesis and acyl-coenzyme A synthetase activities. The key products and services to be delivered through this 2-year award (7/2/2024 - 5/31/2026) include: Developing a new "fatty acid alkyne...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $700,288 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of South Florida (USF) to conduct phenotype-based screens and functional genomics research to identify genetic factors associated with gametocyte development in Plasmodium falciparum, the major global cause of malaria. The project, running from November 2024 to October 2029, will use a random piggyBac mutagenesis approach to...
This federal Project Grant award of $3,762,999.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to advance malaria transmission-blocking vaccine discovery. The research will provide the first comprehensive catalog of surface-exposed proteins in Plasmodium falciparum gametes, zygotes, and ookinetes, with the goal of identifying promising transmission-blocking vaccine (TBV) candidates. Key activities include mass...
The federal Project Grant award of $459,131, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports research to identify essential functions of the mitochondrion in malaria parasites. The goal is to uncover novel drug targets within the parasite mitochondrion that could lead to the development of new antimalarial treatments effective against both symptomatic and transmission stages of malaria...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $702,204 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the London School of Hygiene and Tropical Medicine (LSHTM) to conduct research on complex malaria in India. The key products and services to be delivered through this 5-year project include: Monitoring the changing epidemiology of malaria in Odisha, India through a 4-year community-based cohort study to...

PROTEIN GLYCOSYLATION AND TRAFFICKING IN PLASMODIUM FALCIPARUM - PROJECT SUMMARY IN ALL DOMAINS OF LIFE PROTEINS ARE MODIFIED VIA GLYCOSYLATION. THIS ADDITION OF SUGAR MOLECULES TO PROTEINS IS CRITICAL FOR THEIR FOLDING, FUNCTION, AND RECOGNITION BY THEIR PARTNERS. RIGOROUS STUDIES HAVE SHOWN THAT IN WELL-STUDIED EUKARYOTIC ORGANISMS, PROTEINS SYNTHESIZED IN THE ENDOPLASMIC RETICULUM (ER) ARE GLYCOSYLATED ON ASPARAGINE RESIDUES AS WELL AS ON SERINE OR THREONINE RESIDUES. THESE MODIFICATIONS ARE CRITICAL FOR THE TRAFFICKING OF PROTEINS IN THE SECRETORY PATHWAY. PROTEIN GLYCOSYLATION ACTS AS A MARKER FOR PROTEIN FOLDING TO ENSURE ONLY FOLDED AND FUNCTIONAL PROTEINS ARE SENT FROM THE ER. ONCE OUTSIDE THE ER, GLYCANS ON PROTEINS ALSO ACT AS CRITICAL RECOGNITION MOTIFS TO ROUTE PROTEINS ACCURATELY TO THEIR CORRECT SUBCELLULAR LOCATION. THESE GLYCAN-CENTRIC MECHANISMS ARE FOUND IN ALMOST ALL WELL STUDIED EUKARYOTES. SURPRISINGLY, THE INTRACELLULAR EUKARYOTIC PARASITE, PLASMODIUM FALCIPARUM, DOES NOT APPEAR TO UTILIZE ANY OF THESE CANONICAL PROTEIN GLYCOSYLATION-BASED MECHANISMS TO TRAFFIC PROTEINS IN ITS SECRETORY PATHWAY. THIS PARASITE CAUSES MALARIA, AND THE CLINICAL SYMPTOMS OF MALARIA ARE A DIRECT RESULT OF ITS GROWTH AND EXPANSION WITH HUMAN RED BLOOD CELLS (RBC). THE PARASITE DEPENDS UPON PROTEIN SECRETION TO ENSURE ITS SURVIVAL WITHIN THE RBC. EVEN THOUGH GLYCAN MODIFICATIONS ON PROTEINS ARE A MAJOR DRIVER OF IMMUNE RESPONSES, WE DO NOT KNOW IF AND HOW P. FALCIPARUM GLYCOSYLATES PROTEINS IN ITS SECRETORY PATHWAY DURING THE CLINICALLY RELEVANT ASEXUAL BLOOD STAGES. IN FACT, THE P. FALCIPARUM GENOME LACKS SEVERAL GENES IN THIS PATHWAY THAT ARE WELL CONSERVED IN OTHER EUKARYOTIC ORGANISMS, INCLUDING OTHER CLOSELY RELATED PARASITES. TO FILL THIS MAJOR GAP IN OUR KNOWLEDGE, WE WILL COMBINE GENETIC AND CELLULAR ASSAYS TO STUDY IF CONDITIONAL KNOCKDOWN OF THE TARGETED GLYCOSYLTRANSFERASES INHIBITS PROTEIN TRAFFICKING WITHIN THE HIGHLY BRANCHED AND UNCONVENTIONAL SECRETORY PATHWAY OF P. FALCIPARUM. OUR PRELIMINARY DATA SHOW THAT THE PARASITE PROTEIN GLYCOSYLATION PATHWAY GENES ARE ESSENTIAL FOR PARASITE GROWTH WITHIN THE RBC. THE EXPERIMENTAL APPROACH WILL TEST IF PROTEIN GLYCOSYLATION ALSO FUNCTIONS IN AN UNCONVENTIONAL PROTEIN QUALITY CONTROL PATHWAY IN THE PARASITE ER. WE WILL UTILIZE GLYCOPROTEOMIC APPROACHES TO DETERMINE THE LANDSCAPE OF PROTEIN GLYCOSYLATION DURING THE INTRAERYTHROCYTIC GROWTH OF P. FALCIPARUM. THE COLLABORATIVE RESEARCH TEAM WILL COMBINE THESE PROTEOMIC APPROACHES WITH GENETIC TOOLS TO DETERMINE WHICH GLYCOSYLTRANSFERASES ARE RESPONSIBLE FOR WHICH THE GLYCAN MODIFICATIONS. THE SPECIFIC GLYCOSYLTRANSFERASE ACTIVITIES WILL BE VALIDATED USING COMPLEMENTATION ASSAYS AS WELL AS IN VITRO ASSAYS USING RECOMBINANTLY EXPRESSED GLYCOSYLTRANSFERASE. THE TOOLS AND REAGENTS DEVELOPED FOR THIS PROJECT MAY FIND WIDER APPLICABILITY IN GLYCOBIOLOGY AND PARASITOLOGY. GIVEN THE IMPORTANCE OF GLYCANS IN DRIVING THE HOST IMMUNE SYSTEM, THE PROPOSED STUDIES MAY HAVE IMPORTANT IMPLICATIONS FOR OUR UNDERSTANDING OF THE ANTIMALARIAL IMMUNE RESPONSE.

Posted 6/6/24, 12:00 AM